QIAGEN N.V. research snapshot
QGEN AI stock analysis currently reads QIAGEN N.V. as a high-quality molecular testing and research tools business with a meaningful consumables base, broad customer relationships, and strong free cash flow. The stock closed at $41.40 on July 31, 2026, implying a market value near $8.56 billion. QIAGEN reported 2025 net sales of $2.09 billion and net income of $424.9 million, and company-defined free cash flow of $453.3 million. Q1 2026 sales rose 2% on a reported basis to $492 million but declined 1% at constant exchange rates, and management kept its full-year 2026 outlook at about 1% to 2% CER sales growth with adjusted diluted EPS of at least $2.43 CER. The main QGEN AI stock forecast question is whether Sample technologies, QIAcuity, QIAGEN Digital Insights, QIAstat-Dx, and QuantiFERON can restore growth without weakening cash generation, increasing leverage, or stretching the dividend payout, which stood above 100% of trailing GAAP EPS. Reports of early private equity interest near or above $50 per share add an event-driven layer, and Q2 2026 results are scheduled for August 5, 2026. This page is informational research, not investment advice.
Current price
$41.40 close on July 31, 2026
Market cap
$8.56 billion calculated from $41.40 x 206.80 million shares, with a 0.02% variance versus the reported market cap
AI score
70 / 100
Rating
High-quality molecular testing franchise with recurring consumables and strong cash flow, but the 2026 growth reset, elevated dividend payout, and event-driven takeover speculation temper confidence
Trend status
Price is above the 50-day average near $38.66 but below the 200-day average near $43.85, with neutral long-term and positive short-term momentum
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | QIAGEN sells sample preparation, molecular testing, digital PCR, genomics, bioinformatics, and automation solutions. Q1 2026 consumables and related revenue were about 90% of sales, supporting recurring demand. | High |
| Moat | The moat comes from validated workflows, installed instruments, consumables pull-through, regulatory know-how, proprietary assays, software content, and relationships with more than 500,000 customers. | Medium-high |
| Management | CEO Thierry Bernard and CFO Roland Sackers have focused the portfolio on five growth pillars, completed Genoox and Parse acquisitions, and proposed a 40% dividend increase approved at the 2026 AGM. The test is whether returns and acquisitions improve per-share economics after the 2026 growth reset. | Medium |
| Financial trend | FY2025 revenue rose 5.65% to $2.09 billion and net income reached $424.9 million, while free cash flow was $453.3 million. Q1 2026 revenue grew 2% reported but fell 1% at CER, and free cash flow fell to about $54 million from $96 million. | High |
| Valuation | At $41.40, tool-checked valuation was about 21.34x trailing GAAP EPS, 2.56x book value, 20.80x TTM free cash flow per share reported by StockAnalysis, and 5.82% on the listed annual dividend. | High |
| Technical trend | The price is above the 50-day average near $38.66 but below the 200-day average near $43.85. RSI near 57.63 shows neutral momentum, while ChartMill reads the short-term trend as up and the long-term trend as neutral. | Medium-high |
| Risk level | Risk is medium-high because 2026 growth guidance was cut, Q1 cash and investments fell after a synthetic repurchase, total debt was about $1.67 billion, the TTM dividend payout was above 100% of GAAP EPS, and product, regulatory, tariff, currency, and takeover-event risks remain. | High |
| AI confidence | The AI research has strong factual support for reported results and business structure, but price ranges depend on product adoption, Q2 execution, margin recovery, and the multiple investors assign to diagnostics growth. | Medium-high |
| Investment certainty | Investment certainty is medium rather than high. The business is understandable and cash generative, but the current price requires evidence that the growth pillars can offset weaker QuantiFERON and cautious U.S. Life Sciences demand. | Medium |
QGEN AI stock forecast
The QGEN AI stock forecast uses a three-year sensitivity exercise around the $41.40 closing price and the company 2026 adjusted EPS floor of $2.43. With 10%, 6%, and 2% annual EPS growth and terminal P/E assumptions of 24x, 19x, and 15x, financial_rigor.py produced reference values of $77.6, $55.0, and $38.7. These are model outputs, not promises or analyst targets. The wide range reflects the uncertainty around growth recovery, leverage, currency, multiple compression, and the fate of takeover speculation.
$56 to $78
More likely if the five growth pillars return to mid-single-digit or better CER growth, Sample technologies and QIAcuity scale, QDI AI products convert to recurring software revenue, QuantiFERON demand stabilizes, free cash flow supports debt reduction and shareholder returns, or a confirmed takeover approach near or above the reported $50-per-share interest level emerges.
$45 to $58
More likely if QIAGEN delivers a gradual recovery from the 1% to 2% CER 2026 outlook, maintains strong gross margins, keeps the dividend payout at a sustainable level, and earns a moderate quality-business multiple close to the analyst consensus target of about $44.07 without a large expansion in leverage.
$34 to $41
More likely if U.S. Life Sciences budgets stay cautious, QuantiFERON immigration testing remains weak, product launches or regulatory clearances slip, tariffs and currency pressure margins, takeover interest fades, or debt, cash flow, and an elevated dividend payout compress the multiple below the current level.
QGEN AI technical analysis
QGEN AI technical analysis starts from the $41.40 July 31, 2026 close. StockAnalysis listed a 50-day moving average near $38.66, a 200-day moving average near $43.85, RSI near 57.63, average 20-day volume near 2.82 million shares, and beta near 0.64. ChartMill listed support around $40.93 to $41.24 and $39.79 to $39.93 with horizontal support near $37.99, and resistance around $41.52 to $42.29 with a higher weekly resistance near $54.52. Because this static page does not fetch request-time chart data, confirm all levels with a live chart before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $41.40 | StockAnalysis closing quote on July 31, 2026. The close sat near the middle of the $40.96 to $41.57 daily range after the post-takeover-news move faded. |
| Near support | $40.93 to $41.24 | ChartMill listed this support zone from trend lines and moving averages; the 20-day and 10-day SMAs were near $40.93 and $41.24. A sustained break would weaken the immediate setup. |
| Deeper support | $37.99 to $39.93 | ChartMill listed horizontal support near $37.99 and a secondary support zone near $39.79 to $39.93. This is a deeper reference zone if the consolidation unwinds. |
| Near resistance | $41.52 to $42.29 | ChartMill listed a resistance zone around $41.52 to $42.29, just above the July 31 close. A close through it would open a test of the 200-day average. |
| 200-day moving average | About $43.85 | Both StockAnalysis and ChartMill placed the 200-day average near $43.85. Price remained below this longer trend reference at the cutoff. |
| Higher resistance | $54.52 | ChartMill listed a weekly horizontal resistance near $54.52, above the 52-week high area reached in mid-2025. |
| 50-day moving average | About $38.66 | StockAnalysis technical snapshot around July 31, 2026. Price remained above this shorter trend reference. |
| Momentum and volume | RSI about 57.63; MACD about -0.09 | RSI is in neutral territory, while the daily MACD is slightly below zero. The July 9 move printed about 12.66 million shares, far above the recent average, and volume has since normalized. |
| Volatility and invalidation | Beta about 0.64; ATR about 2.86% | The beta is below the market average, but event-driven gaps can still be material. A sustained close below $37.99 would invalidate the consolidation setup. |
QGEN AI trading strategy
The QGEN AI trading strategy is a rules-based research framework, not personalized advice. It should be paired with live chart checks, position sizing, earnings-calendar review, and fresh filings because QGEN can move on regulatory, product, currency, acquisition, and takeover news. Q2 2026 results are scheduled for August 5, 2026.
Wait for QGEN to reclaim and hold the roughly $43.85 200-day average, then watch whether price clears the $41.52 to $42.29 near-resistance zone on rising volume. Confirm the move with Q2 sales, growth-pillar progress, and cash flow rather than price alone.
A failed reclaim or a close below $40.93 weakens the short-term setup. A break below $37.99 is a broader invalidation reference.
If QGEN holds the $40.93 to $41.24 area, monitor whether the rebound is supported by stable 2026 guidance, improving QuantiFERON trends, Sample technologies growth, and continued QIAcuity and QDI adoption.
Do not average down solely because the price reaches support. Reassess if Q2 guidance, free cash flow, debt, the dividend payout, or regulatory milestones deteriorate.
Track CER sales by Sample technologies, Diagnostic solutions, PCR, and Genomics or NGS; adjusted EPS; gross and operating margins; free cash flow; debt; dividend payout; share count; Parse integration; regulatory progress for QIAstat-Dx panels; and any takeover developments.
Reduce confidence if growth depends on acquisitions without improving organic demand, if leverage stays elevated, if the dividend payout stays above 100% of GAAP earnings, or if adjusted results widen materially from GAAP results.
Investment research summary
Customers pay QIAGEN to turn biological samples into usable molecular information. The company sells the sample preparation, assays, instruments, automation, software, and interpretation layers that help researchers, pharmaceutical companies, and clinical laboratories move from sample to insight.
The moat is a workflow system rather than a single product. Validated protocols, regulatory clearances, installed instruments, consumables pull-through, curated genomic knowledge, and customer relationships can make switching costly. The moat is strongest where QIAGEN controls the full workflow and weakest where tools are interchangeable.
The failure path can begin with a weak quarter and become structural. QIAGEN could lose momentum if research budgets stay constrained, new panels fail to gain adoption, competitors improve faster, regulation delays launches, QuantiFERON demand remains unusually weak, or acquisitions add cost without enough recurring revenue.
Thierry Bernard has led QIAGEN as CEO since 2020, while Roland Sackers has served as CFO since 2004. Management is allocating capital to automation, digital tools, AI-enabled bioinformatics, targeted acquisitions, and a 40% dividend increase approved at the 2026 AGM. The governance test is whether shareholder returns remain disciplined while debt, integration demands, and the above-100% dividend payout rise.
Molecular diagnostics, precision medicine, single-cell analysis, digital PCR, clinical bioinformatics, and antimicrobial resistance testing support long-term demand for molecular workflows. This is a durable healthcare and research trend, but adoption depends on reimbursement, lab budgets, regulatory clearance, and evidence of better outcomes or lower cost.
The price is not demanding by the standards of a high-growth software company, but it still requires a recovery from the 2026 growth reset. A 21.34x trailing P/E, a 16.74x forward P/E, and a roughly 5.82% listed dividend yield provide some support, while about $1.67 billion of total debt, a TTM dividend payout above 100% of GAAP earnings, weaker Q1 free cash flow, and the stock price below its 200-day average reduce the margin of safety.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| QGEN closing price | $41.40 on July 31, 2026 | StockAnalysis historical price data | August 3, 2026 |
| Market cap and shares | $8.56B market cap; 206.80M shares | StockAnalysis statistics and market-cap calculation | August 3, 2026 |
| TTM revenue, net income, and EPS | $2.10B revenue; $402.17M net income; $1.94 EPS | StockAnalysis financial data | August 3, 2026 |
| Q1 2026 net sales | $492M, +2% reported, -1% at CER | QIAGEN full Q1 2026 results | August 3, 2026 |
| Q1 2026 EPS | GAAP $0.33; adjusted $0.54 CER | QIAGEN full Q1 2026 results | August 3, 2026 |
| 2026 outlook | About 1% to 2% CER sales growth; adjusted diluted EPS at least $2.43 CER | QIAGEN full Q1 2026 results | August 3, 2026 |
| Q1 2026 cash and debt | $646.3M cash and investments; $1.65B total debt | StockAnalysis quarterly balance sheet | August 3, 2026 |
| TTM free cash flow | $411.19M; $1.99 FCF per share | StockAnalysis cash flow data | August 3, 2026 |
| Technical snapshot | 50-day average $38.66; 200-day average $43.85; RSI 57.63; beta 0.64 | StockAnalysis statistics | August 3, 2026 |
| Support and resistance snapshot | Support near $40.93 to $41.24, $39.79 to $39.93, and $37.99; resistance near $41.52 to $42.29 and $54.52 | ChartMill technical analysis | August 3, 2026 |
| Analyst consensus | Buy rating; average price target $44.07 | StockAnalysis forecast data | August 3, 2026 |
| Takeover interest reports | Early PE interest from EQT, Advent, and KKR; some suitors reportedly considering at least $50 per share | Reuters and Bloomberg reports via StockAnalysis news | August 3, 2026 |
| Dividend | $2.41 annual; 5.82% yield; 136.08% TTM payout ratio | StockAnalysis statistics and dividend data | August 3, 2026 |
This QGEN AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
